Quantcast

Latest Questcor Pharmaceuticals Inc. Stories

2014-08-14 16:27:16

- Creates a diversified, high-growth therapeutic portfolio, capable of delivering substantial, sustainable value for shareholders DUBLIN, Aug. 14, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has completed its acquisition of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) in a cash and stock transaction valued at approximately $5.8 billion. The acquisition is expected to be immediately accretive to Mallinckrodt's...

2014-08-14 12:28:49

DUBLIN and ANAHEIM, Calif., Aug. 14, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today jointly announced that all proposals necessary for Mallinckrodt's acquisition of Questcor were approved by Mallinckrodt's and Questcor's shareholders at each company's respective shareholder meeting held today. As previously announced, on April 7, 2014, Mallinckrodt and Questcor entered into a definitive agreement by which Mallinckrodt will...

2014-08-04 08:27:04

DUBLIN and ANAHEIM, Calif., Aug. 4, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt") and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) ("Questcor") today jointly announced that two leading independent proxy advisory firms, Institutional Shareholder Services Inc. (ISS) and Glass Lewis, have recommended a vote FOR the binding proposals relating to Mallinckrodt's acquisition of Questcor pursuant to the Agreement and Plan of Merger dated April 5, 2014 (the "Merger")....

2014-07-24 08:34:45

Net Sales $279 Million; Increase of 42% over Prior Year Non-GAAP Results ANAHEIM, Calif., July 24, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the second quarter ended June 30, 2014. Three Months Ended Three Months Ended 06/30/14 06/30/13 Percentage Change --------------------- --------------------- ----------------- GAAP Net Sales...

2014-07-14 08:26:11

--Registration Statement on Form S-4 Declared Effective by SEC-- DUBLIN and ANAHEIM, Calif., July 14, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC") by Mallinckrodt plc on May 16, 2014 and amended on July 11, 2014, which includes a joint proxy statement of Mallinckrodt and Questcor that also constitutes a...

2014-06-23 08:29:39

- Initiates Global Footprint, Diversifies Business, Enhances Long-term Growth Prospects - ANAHEIM, Calif., June 23, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the transaction acquiring rights to Synacthen(®) and Synacthen(®) Depot from Novartis Pharma AG and Novartis AG in certain countries outside the U.S. has now closed. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid...

2014-06-03 12:38:56

Company sponsors Walk to End Lupus Now(TM) events and employees show support for people with the disease during Lupus Awareness Month HAYWARD, Calif., June 3, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced its sponsorship of the Lupus Foundation of America's (LFA) eight national office Walk to End Lupus Now(TM) events and its support of a variety of Lupus Awareness Month activities. Questcor supported numerous lupus awareness, education and...

2014-05-28 16:27:07

HAYWARD, Calif., May 28, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has been honored with a "Recognition of Appreciation" Award from MS Views & News, Inc., a leading multiple sclerosis (MS) education, information and advocacy organization. "We are very proud to recognize Questcor for its exemplary support in helping to provide services to the multiple sclerosis community," said Stuart Schlossman, President and founder of MS Views...

2014-05-14 08:32:08

- Expands pipeline and broadens platform with next-generation melanocortin peptides - ANAHEIM, Calif., May 14, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has entered into a development collaboration agreement with an undisclosed privately held European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. Along with the June 2013 acquisition of Synacthen(®),...

2014-05-05 08:30:03

- Significant clinical response to Acthar was observed in patients experiencing active disease while on conventional SLE maintenance therapies - ANAHEIM, Calif., May 5, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from the first modern clinical study examining the use of H.P. Acthar® Gel (repository corticotropin injection) in systemic lupus erythematosus (SLE) has been published in the journal LUPUS. This independent investigator-initiated...